{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:47:20Z","timestamp":1792806440657,"version":"4.5.0"},"reference-count":87,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Volkswagen-Stiftung","award":["AZ-9B783-M.M.\/S.B.T."],"award-info":[{"award-number":["AZ-9B783-M.M.\/S.B.T."]}]},{"name":"Volkswagen-Stiftung","award":["401821119, Research Training Group GRK2504"],"award-info":[{"award-number":["401821119, Research Training Group GRK2504"]}]},{"name":"Volkswagen-Stiftung","award":["GRK2504"],"award-info":[{"award-number":["GRK2504"]}]},{"name":"Volkswagen-Stiftung","award":["M.M.\/H.S. AZ2022.073.1"],"award-info":[{"award-number":["M.M.\/H.S. AZ2022.073.1"]}]},{"name":"Volkswagen-Stiftung","award":["DeeP-CMV\/AP-5\/M.M."],"award-info":[{"award-number":["DeeP-CMV\/AP-5\/M.M."]}]},{"name":"Deutsche Forschungsgemeinschaft (DFG)","award":["AZ-9B783-M.M.\/S.B.T."],"award-info":[{"award-number":["AZ-9B783-M.M.\/S.B.T."]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Deutsche Forschungsgemeinschaft (DFG)","award":["401821119, Research Training Group GRK2504"],"award-info":[{"award-number":["401821119, Research Training Group GRK2504"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Deutsche Forschungsgemeinschaft (DFG)","award":["GRK2504"],"award-info":[{"award-number":["GRK2504"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Deutsche Forschungsgemeinschaft (DFG)","award":["M.M.\/H.S. AZ2022.073.1"],"award-info":[{"award-number":["M.M.\/H.S. AZ2022.073.1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Deutsche Forschungsgemeinschaft (DFG)","award":["DeeP-CMV\/AP-5\/M.M."],"award-info":[{"award-number":["DeeP-CMV\/AP-5\/M.M."]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research Training Group","award":["AZ-9B783-M.M.\/S.B.T."],"award-info":[{"award-number":["AZ-9B783-M.M.\/S.B.T."]}]},{"name":"Research Training Group","award":["401821119, Research Training Group GRK2504"],"award-info":[{"award-number":["401821119, Research Training Group GRK2504"]}]},{"name":"Research Training Group","award":["GRK2504"],"award-info":[{"award-number":["GRK2504"]}]},{"name":"Research Training Group","award":["M.M.\/H.S. AZ2022.073.1"],"award-info":[{"award-number":["M.M.\/H.S. AZ2022.073.1"]}]},{"name":"Research Training Group","award":["DeeP-CMV\/AP-5\/M.M."],"award-info":[{"award-number":["DeeP-CMV\/AP-5\/M.M."]}]},{"name":"Wilhelm Sander-Stiftung","award":["AZ-9B783-M.M.\/S.B.T."],"award-info":[{"award-number":["AZ-9B783-M.M.\/S.B.T."]}]},{"name":"Wilhelm Sander-Stiftung","award":["401821119, Research Training Group GRK2504"],"award-info":[{"award-number":["401821119, Research Training Group GRK2504"]}]},{"name":"Wilhelm Sander-Stiftung","award":["GRK2504"],"award-info":[{"award-number":["GRK2504"]}]},{"name":"Wilhelm Sander-Stiftung","award":["M.M.\/H.S. AZ2022.073.1"],"award-info":[{"award-number":["M.M.\/H.S. AZ2022.073.1"]}]},{"name":"Wilhelm Sander-Stiftung","award":["DeeP-CMV\/AP-5\/M.M."],"award-info":[{"award-number":["DeeP-CMV\/AP-5\/M.M."]}]},{"name":"Bayerische Forschungsstiftung","award":["AZ-9B783-M.M.\/S.B.T."],"award-info":[{"award-number":["AZ-9B783-M.M.\/S.B.T."]}],"id":[{"id":"https:\/\/ror.org\/00emnts94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bayerische Forschungsstiftung","award":["401821119, Research Training Group GRK2504"],"award-info":[{"award-number":["401821119, Research Training Group GRK2504"]}],"id":[{"id":"https:\/\/ror.org\/00emnts94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bayerische Forschungsstiftung","award":["GRK2504"],"award-info":[{"award-number":["GRK2504"]}],"id":[{"id":"https:\/\/ror.org\/00emnts94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bayerische Forschungsstiftung","award":["M.M.\/H.S. AZ2022.073.1"],"award-info":[{"award-number":["M.M.\/H.S. AZ2022.073.1"]}],"id":[{"id":"https:\/\/ror.org\/00emnts94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bayerische Forschungsstiftung","award":["DeeP-CMV\/AP-5\/M.M."],"award-info":[{"award-number":["DeeP-CMV\/AP-5\/M.M."]}],"id":[{"id":"https:\/\/ror.org\/00emnts94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The repertoire of currently available antiviral drugs spans therapeutic applications against a number of important human pathogens distributed worldwide. These include cases of the pandemic severe acute respiratory coronavirus type 2 (SARS-CoV-2 or COVID-19), human immunodeficiency virus type 1 (HIV-1 or AIDS), and the pregnancy- and posttransplant-relevant human cytomegalovirus (HCMV). In almost all cases, approved therapies are based on direct-acting antivirals (DAAs), but their benefit, particularly in long-term applications, is often limited by the induction of viral drug resistance or side effects. These issues might be addressed by the additional use of host-directed antivirals (HDAs). As a strong input from long-term experiences with cancer therapies, host protein kinases may serve as HDA targets of mechanistically new antiviral drugs. The study demonstrates such a novel antiviral strategy by targeting the major virus-supportive host kinase CDK7. Importantly, this strategy focuses on highly selective, 3D structure-derived CDK7 inhibitors carrying a warhead moiety that mediates covalent target binding. In summary, the main experimental findings of this study are as follows: (1) the in vitro verification of CDK7 inhibition and selectivity that confirms the warhead covalent-binding principle (by CDK-specific kinase assays), (2) the highly pronounced antiviral efficacies of the hit compounds (in cultured cell-based infection models) with half-maximal effective concentrations that reach down to picomolar levels, (3) a particularly strong potency of compounds against strains and reporter-expressing recombinants of HCMV (using infection assays in primary human fibroblasts), (4) additional activity against further herpesviruses such as animal CMVs and VZV, (5) unique mechanistic properties that include an immediate block of HCMV replication directed early (determined by Western blot detection of viral marker proteins), (6) a substantial drug synergism in combination with MBV (measured by a Loewe additivity fixed-dose assay), and (7) a strong sensitivity of clinically relevant HCMV mutants carrying MBV or ganciclovir resistance markers. Combined, the data highlight the huge developmental potential of this host-directed antiviral targeting concept utilizing covalently binding CDK7 inhibitors.<\/jats:p>","DOI":"10.3390\/pharmaceutics16020158","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:35:40Z","timestamp":1706070940000},"page":"158","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity"],"prefix":"10.3390","volume":"16","author":[{"given":"DongHoon","family":"Yu","sequence":"first","affiliation":[{"name":"Qurient Co., Ltd., C-Dong, 242 Pangyo-ro, C801 Bundang-gu, Seongnam-si 13487, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wagner","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Sch\u00fctz","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeejin","family":"Jeon","sequence":"additional","affiliation":[{"name":"Qurient Co., Ltd., C-Dong, 242 Pangyo-ro, C801 Bundang-gu, Seongnam-si 13487, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mooyoung","family":"Seo","sequence":"additional","affiliation":[{"name":"Qurient Co., Ltd., C-Dong, 242 Pangyo-ro, C801 Bundang-gu, Seongnam-si 13487, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeseung","family":"Kim","sequence":"additional","affiliation":[{"name":"Qurient Co., Ltd., C-Dong, 242 Pangyo-ro, C801 Bundang-gu, Seongnam-si 13487, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Br\u00fcckner","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintawee","family":"Kicuntod","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tillmanns","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wangen","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8416","authenticated-orcid":false,"given":"Friedrich","family":"Hahn","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-2695","authenticated-orcid":false,"given":"Benedikt B.","family":"Kaufer","sequence":"additional","affiliation":[{"name":"Institute of Virology, Freie Universit\u00e4t Berlin, Robert-von-Ostertag-Stra\u00dfe 7\u201313, 14163 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Neipel","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5537-438X","authenticated-orcid":false,"given":"Jan","family":"Eickhoff","sequence":"additional","affiliation":[{"name":"Lead Discovery Center GmbH, Otto-Hahn-Stra\u00dfe 15, 44227 Dortmund, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5475-9053","authenticated-orcid":false,"given":"Bert","family":"Klebl","sequence":"additional","affiliation":[{"name":"Lead Discovery Center GmbH, Otto-Hahn-Stra\u00dfe 15, 44227 Dortmund, Germany"},{"name":"The Norwegian College of Fishery Science UiT, Arctic University of Norway, 9037 Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyean","family":"Nam","sequence":"additional","affiliation":[{"name":"Qurient Co., Ltd., C-Dong, 242 Pangyo-ro, C801 Bundang-gu, Seongnam-si 13487, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Marschall","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virolosgy, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., and Ohmori, T. (2018). Receptor Tyrosine Kinase-Targeted Cancer Therapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113491"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106362","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e142241","DOI":"10.1172\/JCI142241","article-title":"Insulin signaling in health and disease","volume":"131","author":"Saltiel","year":"2021","journal-title":"J. Clin. Investg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41577-022-00734-z","article-title":"Host-directed immunotherapy of viral and bacterial infections: Past, present and future","volume":"23","author":"Wallis","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00168-19","DOI":"10.1128\/CMR.00168-19","article-title":"Host-Directed Antiviral Therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MCP.0000000000000769","article-title":"Host-directed therapies for COVID-19","volume":"27","author":"Maeurer","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tripp, R.A., and Martin, D.E. (2023). Screening Drugs for Broad-Spectrum, Host-Directed Antiviral Activity: Lessons from the Development of Probenecid for COVID-19. Viruses, 15.","DOI":"10.3390\/v15112254"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100058","DOI":"10.1016\/j.crphar.2021.100058","article-title":"Host directed therapies: COVID-19 and beyond","volume":"2","author":"Tripathi","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ginex, T., Garaigorta, U., Ram\u00edrez, D., Castro, V., Nozal, V., Maestro, I., Garc\u00eda-C\u00e1rceles, J., Campillo, N.E., Martinez, A., and Gastaminza, P. (2021). Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico\/In Vitro Screening Methods. Pharmaceuticals, 14.","DOI":"10.3390\/ph14040332"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01534-14","DOI":"10.1128\/mBio.01534-14","article-title":"Host-directed antimicrobial drugs with broad-spectrum efficacy against intracellular bacterial pathogens","volume":"5","author":"Potluri","year":"2014","journal-title":"mBio"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/MOP.0000000000001176","article-title":"Host-directed immunotherapy to fight infectious diseases","volume":"34","author":"Langelier","year":"2022","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Schloer, S., Goretzko, J., and Rescher, U. (2022). Repurposing Antifungals for Host-Directed Antiviral Therapy?. Pharmaceuticals, 15.","DOI":"10.3390\/ph15020212"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100423","DOI":"10.1016\/j.xcrm.2021.100423","article-title":"Host-directed therapy, an untapped opportunity for antimalarial intervention","volume":"2","author":"Wei","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4254\/wjh.v8.i2.123","article-title":"Ribavirin: Past, present and future","volume":"8","author":"Jacques","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","article-title":"Ribavirin\u2019s antiviral mechanism of action: Lethal mutagenesis?","volume":"80","author":"Crotty","year":"2002","journal-title":"J. Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","article-title":"Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection","volume":"37","author":"Feld","year":"2017","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104247","DOI":"10.1016\/j.jcv.2019.104247","article-title":"Antiviral activity of ribavirin and favipiravir against human astroviruses","volume":"123","author":"Janowski","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s00018-005-5455-y","article-title":"The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus","volume":"63","author":"Dixit","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin\u2014Current status of a broad spectrum antiviral agent","volume":"2","author":"Snell","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_21","first-page":"5447","article-title":"Maraviroc: A review of its use in HIV infection and beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/135965350901400514","article-title":"Maraviroc: Pharmacokinetics and drug interactions","volume":"14","author":"Abel","year":"2009","journal-title":"Antivir. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"De Luca, A., Pezzotti, P., Boucher, C., D\u00f6ring, M., Incardona, F., Kaiser, R., Lengauer, T., Pfeifer, N., Sch\u00fclter, E., and Vandamme, A.M. (2019). Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0225381"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2146\/ajhp080206","article-title":"Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection","volume":"66","author":"Yost","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Brillanti, S. (2022). Management of Delta Hepatitis 45 Years after the Discovery of HDV. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061587"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100686","DOI":"10.1016\/j.jhepr.2023.100686","article-title":"Treating hepatitis D with bulevirtide\u2014Real-world experience from 114 patients","volume":"5","author":"Tacke","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: First Approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.13811","article-title":"Bulevirtide-based treatment strategies for chronic hepatitis delta: A review","volume":"30","author":"Degasperi","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Malumbres, M. (2014). Cyclin-dependent kinases. Genome Biol., 15.","DOI":"10.1186\/gb4184"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: A changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2007.10.012","article-title":"CDK inhibitors in cancer therapy: What is next?","volume":"29","author":"Malumbres","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_34","first-page":"S45","article-title":"Cyclins and related kinases in cancer cells","volume":"12","author":"Malumbres","year":"2007","journal-title":"J. BUON"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.coph.2008.06.013","article-title":"Emerging cancer therapeutic opportunities by inhibiting mitotic kinases","volume":"8","author":"Montoya","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Abdelmalak, M., Singh, R., Anwer, M., Ivanchenko, P., Randhawa, A., Ahmed, M., Ashton, A.W., Du, Y., Jiao, X., and Pestell, R. (2022). The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance. Cancers, 14.","DOI":"10.3390\/cancers14215388"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tcb.2021.01.010","article-title":"New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy","volume":"31","author":"Bury","year":"2021","journal-title":"Trends Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11523-017-0541-2","article-title":"Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions","volume":"13","author":"Vijayaraghavan","year":"2018","journal-title":"Target. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","article-title":"Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy","volume":"10","author":"Chou","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/bs.apcsb.2022.11.008","article-title":"CDK regulators-Cell cycle progression or apoptosis-Scenarios in normal cells and cancerous cells","volume":"135","author":"Nilmani","year":"2023","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10555-020-09885-8","article-title":"CDK7 inhibitors as anticancer drugs","volume":"39","author":"Sava","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/emboj.2012.94","article-title":"Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion","volume":"31","author":"Ganuza","year":"2012","journal-title":"EMBO J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1128\/AAC.04534-14","article-title":"A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations","volume":"59","author":"Hutterer","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Wild, M., Hahn, F., Br\u00fcckner, N., Sch\u00fctz, M., Wangen, C., Wagner, S., Sommerer, M., Strobl, S., and Marschall, M. (2022). Cyclin-Dependent Kinases (CDKs) and the Human Cytomegalovirus-Encoded CDK Ortholog pUL97 Represent Highly Attractive Targets for Synergistic Drug Combinations. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052493"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wild, M., Kicuntod, J., Seyler, L., Wangen, C., Bertzbach, L.D., Conradie, A.M., Kaufer, B.B., Wagner, S., Michel, D., and Eickhoff, J. (2021). Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020575"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Sch\u00fctz, M., Wangen, C., Sommerer, M., K\u00f6gler, M., Eickhoff, J., Degenhart, C., Klebl, B., Naing, Z., Egilmezer, E., and Hamilton, S.T. (2023). Cytomegalovirus cyclin-dependent kinase ortholog vCDK\/pUL97 undergoes regulatory interaction with human cyclin H and CDK7 to codetermine viral replication efficiency. Virus Res., 335.","DOI":"10.1016\/j.virusres.2023.199200"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1128\/MCB.00595-14","article-title":"Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells","volume":"34","author":"Kelso","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2174\/1570162033485339","article-title":"Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics","volume":"1","author":"Maddukuri","year":"2003","journal-title":"Curr. HIV Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/21541264.2018.1542254","article-title":"Roles of CDKs in RNA polymerase II transcription of the HIV-1 genome","volume":"10","author":"Rice","year":"2019","journal-title":"Transcription"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbapap.2003.11.024","article-title":"Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication","volume":"1697","author":"Schang","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-3788","article-title":"The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo","volume":"25","author":"Zhang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2018.11.008","article-title":"In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model","volume":"161","author":"Sonntag","year":"2019","journal-title":"Antiviral Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1038\/s41467-019-13334-8","article-title":"A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells","volume":"10","author":"Ghezzi","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"664848","DOI":"10.3389\/fonc.2021.664848","article-title":"Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells through CDK7 Inhibition","volume":"11","author":"Peng","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.44.6.1588-1597.2000","article-title":"Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents","volume":"44","author":"Marschall","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Bootz, A., Karbach, A., Spindler, J., Kropff, B., Reuter, N., Sticht, H., Winkler, T.H., Britt, W.J., and Mach, M. (2017). Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006601"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1099\/jgv.0.001370","article-title":"Differential upregulation of host cell protein kinases by the replication of \u03b1-, \u03b2- and \u03b3-herpesviruses provides a signature of virus-specific signalling","volume":"101","author":"Marschall","year":"2020","journal-title":"J. Gen. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Goodwin, T.J., McCarthy, M., Osterrieder, N., Cohrs, R.J., and Kaufer, B.B. (2013). Three-dimensional normal human neural progenitor tissue-like assemblies: A model of persistent varicella-zoster virus infection. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003512"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/JVI.74.14.6324-6332.2000","article-title":"Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells","volume":"74","author":"Molesworth","year":"2000","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jviromet.2017.04.012","article-title":"Development of a robust, higher throughput green fluorescent protein (GFP)-based Epstein-Barr Virus (EBV) micro-neutralization assay","volume":"247","author":"Lin","year":"2017","journal-title":"J. Virol. Methods"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.virol.2004.03.049","article-title":"Use of the red fluorescent protein as a marker of Kaposi\u2019s sarcoma-associated herpesvirus lytic gene expression","volume":"325","author":"Vieira","year":"2004","journal-title":"Virology"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Sch\u00fctz, M., M\u00fcller, R., Socher, E., Wangen, C., Full, F., Wyler, E., Wong, D., Scherer, M., Stamminger, T., and Chou, S. (2022). Highly Conserved Interaction Profiles between Clinically Relevant Mutants of the Cytomegalovirus CDK-like Kinase pUL97 and Human Cyclins: Functional Significance of Cyclin H. Int. J. Mol. Sci., 23.","DOI":"10.21203\/rs.3.rs-1676959\/v1"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"L\u00f6sing, J., H\u00e4ge, S., Sch\u00fctz, M., Wagner, S., Wardin, J., Sticht, H., and Marschall, M. (2022). \u2018Shared-Hook\u2019 and \u2018Changed-Hook\u2019 Binding Activities of Herpesviral Core Nuclear Egress Complexes Identified by Random Mutagenesis. Cells, 11.","DOI":"10.3390\/cells11244030"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13979","DOI":"10.1074\/jbc.M109.063628","article-title":"Novel mode of phosphorylation-triggered reorganization of the nuclear lamina during nuclear egress of human cytomegalovirus","volume":"285","author":"Milbradt","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Milbradt, J., Sonntag, E., Wagner, S., Strojan, H., Wangen, C., Lenac Rovis, T., Lisnic, B., Jonjic, S., Sticht, H., and Britt, W.J. (2018). Human Cytomegalovirus Nuclear Capsids Associate with the Core Nuclear Egress Complex and the Viral Protein Kinase pUL97. Viruses, 10.","DOI":"10.3390\/v10010035"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1074\/jbc.RA118.007049","article-title":"Cyclins B1, T1, and H differ in their molecular mode of interaction with cytomegalovirus protein kinase pUL97","volume":"294","author":"Steingruber","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Tillmanns, J., H\u00e4ge, S., Borst, E.M., Wardin, J., Eickhoff, J., Klebl, B., Wagner, S., Wangen, C., Hahn, F., and Socher, E. (2023). Assessment of Covalently Binding Warhead Compounds in the Validation of the Cytomegalovirus Nuclear Egress Complex as an Antiviral Target. Cells, 12.","DOI":"10.3390\/cells12081162"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1521654031000070645","article-title":"Herpes virus replication","volume":"55","author":"Boehmer","year":"2003","journal-title":"IUBMB Life"},{"key":"ref_69","first-page":"1330","article-title":"Reversible Michael additions: Covalent inhibitors and prodrugs","volume":"12","author":"Johansson","year":"2012","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/17460441.2022.2034783","article-title":"Electrophilic warheads in covalent drug discovery: An overview","volume":"17","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1747-1028-4-1","article-title":"Regulation of the retinoblastoma proteins by the human herpesviruses","volume":"4","author":"Hume","year":"2009","journal-title":"Cell Div."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Hertel, L., Chou, S., and Mocarski, E.S. (2007). Viral and cell cycle\u2013regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030006"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ball, C.B., Parida, M., Li, M., Spector, B.M., Suarez, G.A., Meier, J.L., and Price, D.H. (2022). Human Cytomegalovirus Infection Elicits Global Changes in Host Transcription by RNA Polymerases I, II and III. Viruses, 14.","DOI":"10.3390\/v14040779"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wild, M., Karner, D., Eickhoff, J., Wagner, S., Kicuntod, J., Chang, W., Barry, P., Jonji\u0107, S., Lenac Rovi\u0161, T., and Marschall, M. (2023). Combined Treatment with Host-Directed and Anticytomegaloviral Kinase Inhibitors: Mechanisms, Synergisms and Drug Resistance Barriers. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15122680"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"104711","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antiviral Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Shindo, N., and Ojida, A. (2021). Recent progress in covalent warheads for in vivo targeting of endogenous proteins. Bioorg. Med. Chem., 47.","DOI":"10.1016\/j.bmc.2021.116386"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4155\/fmc-2020-0118","article-title":"Covalent inhibitors: Back on track?","volume":"12","author":"Gehringer","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1039\/D2MD00216G","article-title":"Advanced approaches of developing targeted covalent drugs","volume":"13","author":"Gai","year":"2022","journal-title":"RSC Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","article-title":"A road map for prioritizing warheads for cysteine targeting covalent inhibitors","volume":"160","author":"Petri","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.2174\/1381612824999201105164942","article-title":"Covalent Docking in Drug Discovery: Scope and Limitations","volume":"26","author":"Scarpino","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1039\/D2MD00112H","article-title":"Recent applications of covalent chemistries in protein-protein interaction inhibitors","volume":"13","author":"Chan","year":"2022","journal-title":"RSC Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"McAulay, K., Bilsland, A., and Bon, M. (2022). Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery. Pharmaceuticals, 15.","DOI":"10.3390\/ph15111366"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Zhao, Z., and Bourne, P.E. (2022). Systematic Exploration of Privileged Warheads for Covalent Kinase Drug Discovery. Pharmaceuticals, 15.","DOI":"10.26434\/chemrxiv-2022-nlb0m"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"105422","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4155\/fmc-2020-0236","article-title":"10 years into the resurgence of covalent drugs","volume":"13","year":"2021","journal-title":"Future Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1021\/acs.jcim.3c00720","article-title":"Quantum Descriptors for Predicting and Understanding the Structure-Activity Relationships of Michael Acceptor Warheads","volume":"63","author":"Liu","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Cheke, R.S., and Kharkar, P.S. (2023). Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics. Drug Dev. Res.","DOI":"10.1002\/ddr.22132"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/2\/158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:48:12Z","timestamp":1760104092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/2\/158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":87,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["pharmaceutics16020158"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16020158","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,23]]}}}